A guide to monitoring and evaluation for collaborative TB/HIV activities


2015 revision







The Global Fund





A guide to monitoring and evaluation for collaborative TB/HIV activities

2015 revision



WHO Library Cataloguing-in-Publication Data

A guide to monitoring and evaluation for collaborative TB/HIV activities - 2015 revision.

1.HIV Infections. 2.Acquired Immunodeficiency Syndrome - prevention and control. 3.AIDS-Related Opportunistic Infections - prevention and control. 4.Tuberculosis, Pulmonary - prevention and control. 5.National Health Programs. 6.Health Policy. 7.Guideline. I.World Health Organization.

ISBN 978 92 4 150827 8 (NLM classification: WC 503.5)

© World Health Organization 2015

All rights reserved. Publications of the World Health Organization are available on the WHO website (www.who.int) or can be purchased from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel.: +41 22 791 3264; fax: +41 22 791 4857; e-mail: bookorders@who.int).

Requests for permission to reproduce or translate WHO publications –whether for sale or for non-commercial distribution– should be addressed to WHO Press through the WHO website (www.who.int/about/licensing/copyright_form/en/index.html).

The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps represent approximate border lines for which there may not yet be full agreement.

The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.

All reasonable precautions have been taken by the World Health Organization to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either expressed or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall the World Health Organization be liable for damages arising from its use.

Designed by North Creative, Geneva, Switzerland

Printed in Spain

WHO/HTM/TB/2015.02

WHO/HIV/2015.1

Contents

Ack	now	ledgements	3
Abb	revi	ations	4
1. lr	itrod	luction	5
	1.1	Key changes in the current revision compared to 2009 version	6
	1.2	Aim of the guide	6
	1.3	Target audience	7
	1.4	Categorization of indicators for collaborative TB/HIV activities	7
	1.5	Description of indicators	7
	1.6	Disaggregation by age and sex	8
	1.7	Suggested indicators for health management information system	8
	1.8	Confidentiality considerations	9
2. N	letho	odology for monitoring and evaluation for collaborative TB/HIV activities	10
	2.1	Routine monitoring systems	10
	2.2	Supportive supervision	12
	2.3	Surveillance and surveys	12
	2.4	Country situational analysis	12
	2.5	External programme reviews	12
3. N	lonit	oring and evaluation indicators	13
	3.1	Summary of indicators	13
	3.2	Core global and national indicators for monitoring and reporting	15
	3.3	Core indicators for only national-level monitoring and reporting	22
	3.4	Optional indicators for national-level monitoring and reporting	26
Refe	eren	ces	31
Ann	ex 1	. Brief overview of and rationale for monitoring and evaluation	32
	noM	nitoring and evaluation: what is it and why is it important?	32
	The	monitoring and evaluation framework	32
	Ste	os in developing a monitoring and evaluation plan	33
	Indi	cators	33
Ann	ex 2	. Country profile and situational analysis of collaborative TB/HIV activities	35
	Pop	ulation and services	36
	Disc	ease-specific information	36
	Eva	luation of the mechanisms for TB/HIV collaboration	37
	Ser	vice delivery	41
	Ref	erences: Annex 2	42

Tables

Table 1. WHO recommended collaborative TB/HIV activities	5
Table 2. Priority indicators for health management information system	8
Table 3. Checklist of features of an efficient monitoring and evaluation system	11
Table 4. Summary of indicators for monitoring and evaluations of collaborative TB/HIV activities	13
Table A1.1 Criteria for indicator selection	34
Table A2.1 Country situational analysis	35
Table A2.2 Country TB/HIV policy map	39

Acknowledgements

This revision was based on the WHO *Guide to monitoring and evaluation for collaborative TB/HIV activities* published in 2009. The update was written by Avinash Kanchar and Haileyesus Getahun with contributions from Phillipe Glaziou, Lisa Nelson and Hazim Timimi.

Steering group

Annabel Baddeley (WHO, Geneva), Jacob Dee (PEPFAR TB/HIV Technical Working Group, Centres for Disease Control and Prevention, USA), Taavi Erkkola (UNAIDS, Geneva), Haileyesus Getahun (WHO, Geneva), Phillip Glaziou (WHO, Geneva), Suman Jain (the Global Fund, Geneva), Avinash Kanchar (WHO, Geneva), Lisa Nelson (WHO, Geneva), Alka Aggarwal Singh (the Global Fund, Geneva) and Hazim Timimi (WHO, Geneva).

TB/HIV monitoring and evaluation guide revision group

Oluyemisi Akinwande (Center for Integrated Health Programs, Nigeria), Yibletal Assefa (National HIV/AIDS Prevention and Control Office, Ministry of Health, Ethiopia), Lucy Chesire (Tuberculosis Advocacy Consortium, Kenya), Charlotte Colvin (USAID, TB/Bureau of Global Health, Washington, DC, USA), Stéphane d'Almeida (Programme National de Lutte contre le SIDA et les IST, Togo), Anand Date (Centres for Disease Control and Prevention, USA), Peter Ghys (UNAIDS, Geneva), Peter Godfrey-Faussett (UNAIDS, Geneva), Nathan Kapata (Ministry of Health, Zambia), Bernard Langat (Ministry of Health, Kenya), Boniswa Sharon Seti (Aids and Rights Alliance for Southern Africa, South Africa), Seng Sopheap (National Center for HIV/AIDS Dermatology and STD, Cambodia), Jeroen van Gorkom (KNCV Tuberculosis Foundation, Netherlands), Eliud Wandwalo (the Global Fund, Geneva), Mohammed Yassin (the Global Fund, Geneva).

WHO headquarters, regional offices and country offices

Isabelle Bergeri (WHO, Geneva), Andrei Dadu (WHO Regional Office for Europe), Meg Doherty (WHO, Geneva), Dennis Falzon (WHO, Geneva), Monica Alonso Gonzalez (WHO-PAHO, Washington, DC, USA), Chika Hayashi (WHO, Geneva), Cornelia Hennig (WHO, Viet Nam), Masaya Kato (WHO Regional Office for the Western Pacific), Alberto Matteelli (WHO, Geneva), Rafael Alberto Lopez Olarte (WHO-PAHO, Washington, DC, USA), Harilala Nirina Razakasoa (WHO Regional Office for Africa), Annemarie Stengaard (WHO Regional Office for Europe), Michelle Williams (WHO, Geneva).

Comments were also provided by:

Riitta Dlodlo (the Union, Zimbabwe), Reuben Granich (UNAIDS, Geneva), Max Meis (KNCV Tuberculosis Foundation, Netherlands), Eric Pevzner (Centres for Disease Control and Prevention, USA) and participants in the WHO technical consultation on 3ILPMS (three interlinked patient monitoring systems for HIV Care/ART, MCH/PMTCT and TB/HIV), 11–12 September 2013, Geneva.

Financial acknowledgement

The development of these guidelines was financially supported by the Joint United Nations Programme on HIV/AIDS, UNAIDS Unified Budget, Results and Accountability Framework (UBRAF), and the United States President's Emergency Plan for AIDS Relief (PEPFAR) through the United States Agency for International Development (USAID).

Abbreviations

ART antiretroviral therapy

CBO community-based organization

HIV human immunodeficiency virus

MCH maternal and child health

NACP national AIDS control programmeNGO nongovernmental organization

NTP national TB programme

PEPFAR United States President's Emergency Plan for AIDS Relief

PMTCT prevention of mother-to-child transmission

TB tuberculosis

UNAIDS Joint United Nations Programme on HIV/AIDS

WHO World Health Organization



https://www.yunbaogao.cn/report/index/report?reportId=5_27556



